U.S., Feb. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07434180) titled 'Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary' on Aug. 28, 2025.
Brief Summary: The aim of the study is to test if a new radionuclide therapy, called 177-Lu-FAP-2286, works to treat cancer in patients with Cancer of Unknown Primary (CUP).
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Cancer of Unknown Primary
Intervention:
DRUG: 177Lu-FAP-2286
177Lu-FAP-2286 is a novel radioligand therapy. FAP-2286 is a small molecular ligand that binds to the fibroblast activated protein on cancer associated fibroblasts. Lutetium-177 (177Lu) is a nuclear reactor-produced radiometal with ...